Phoenix Children's Hospital

Running trials

• Recruiting

  BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease

  NCT07582848· Carelon Research· Source

• Recruiting

  Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

  NCT07582861· Carelon Research· Source

• Recruiting

  Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials

  NCT07696065· Early phase 1· Phoenix Children's Hospital· Source

• Recruiting

  Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  NCT07194044· Phase 1· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  A Long-term Follow-up Study in Patients Who Received BEAM-101

  NCT07373639· Beam Therapeutics Inc.· Source

• Recruiting

  A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

  NCT07047144· Phase 2· Scholar Rock, Inc.· Source

• Recruiting

  The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

  NCT06975865· Phase 3· Sanofi· Source

• Recruiting

  A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  NCT07071519· Phase 3· AbbVie· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Recruiting

  Pediatric Down Syndrome Post-Approval Study

  NCT06851338· Inspire Medical Systems, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

  NCT06100289· Phase 3· Takeda· Source

• Recruiting

  Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  NCT06541262· Phase 1/2· Milton S. Hershey Medical Center· Source

• Recruiting

  A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

  NCT05849662· Phase 1/2· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Recruiting

  Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

  NCT06564974· Catalyst Pharmaceuticals, Inc.· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Nicole Hamblett· Source

• Recruiting

  A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  NCT06379789· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  MSC EVs in Dystrophic Epidermolysis Bullosa

  NCT04173650· Phase 1/2· Aegle Therapeutics· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

  NCT06412666· Phase 2/3· Cytokinetics· Source

• Enrolling by invitation

  Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

  NCT06191315· Phase 3· Sanofi· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05995353· Phase 3· AbbVie· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Recruiting

  TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

  NCT05848687· Phase 1/2· Tanja Andrea Gruber· Source

• Active, not recruiting

  Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  NCT05781152· Phase 4· Connecticut Children's Medical Center· Source

• Recruiting

  Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

  NCT06385886· RTI International· Source

• Recruiting

  Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

  NCT04972942· Phase 1· New York Medical College· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  NCT05101551· Phase 1· Norman J. Lacayo· Source

• Recruiting

  A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

  NCT05634369· Phase 1/2· Nationwide Children's Hospital· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Active, not recruiting

  CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

  NCT05440786· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

  NCT05456880· Phase 1/2· Beam Therapeutics Inc.· Source

• Recruiting

  A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

  NCT05265273· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

  NCT05126758· Phase 3· Capricor Inc.· Source

• Active, not recruiting

  Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

  NCT05268094· Carelon Research· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

  NCT04770779· Phase 3· Agios Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

  NCT04337177· Phase 1· Valent Technologies, LLC· Source

• Enrolling by invitation

  Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

  NCT04836390· Phase 2· Michael Pulsipher· Source

• Active, not recruiting

  Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

  NCT04551131· Phase 1/2· St. Jude Children's Research Hospital· Source

• Recruiting

  Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

  NCT04079179· Phase 2· Carl Allen· Source

• Recruiting

  Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

  NCT04040452· Phase 4· Phoenix Children's Hospital· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

  NCT04431726· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

  NCT04177914· University of Utah· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

  NCT04201457· Phase 1/2· Pediatric Brain Tumor Consortium· Source

• Active, not recruiting

  A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

  NCT04175600· Phase 3· Actelion· Source

Showing 50 of 70.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers13 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Congenital heart disease4 recruiting
• Sarcoma4 recruiting
• Acute myeloid leukaemia3 recruiting
• Sickle cell disease3 recruiting
• Crohn's disease2 recruiting
• Spinal muscular atrophy2 recruiting
• Ulcerative colitis2 recruiting
• Aplastic anaemia1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cystic fibrosis1 recruiting
• Down syndrome1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epidermolysis bullosa1 recruiting
• Fabry disease1 recruiting
• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• Hodgkin lymphoma1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Neuroblastoma1 recruiting
• Neurofibromatosis type 11 recruiting
• Obstructive sleep apnoea1 recruiting
• Pompe disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Withdrawn

  Study of a Gene Therapy Treatment for Hemophilia A

  NCT06297486· Phase 3· Spark Therapeutics, Inc.· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Recruiting

  Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

  NCT05416307· Phase 2/3· Electra Therapeutics Inc.· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Rhythm Pharmaceuticals, Inc.· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Scholar Rock, Inc.· Source

• Completed

  Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

  NCT05232929· Phase 4· Genentech, Inc.· Source

• Completed

  A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

  NCT04773782· Phase 1/2· Blueprint Medicines Corporation· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· SK Life Science, Inc.· Source

• Terminated

  A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

  NCT04927247· Phase 3· Pfizer· Source

• Completed

  SurvivorLink: Scalability of an Electronic Personal Health Record

  NCT03543852· Emory University· Source

• Completed

  Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

  NCT04903314· Phase 1· SK Life Science, Inc.· Source

• Completed

  A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Phase 1/2· Eli Lilly and Company· Source

• Terminated

  67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

  NCT04023331· Phase 1/2· Clarity Pharmaceuticals Ltd· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Completed

  CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

  NCT04145349· Phase 1/2· Eli Lilly and Company· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

  NCT03939637· Phase 3· Baylor College of Medicine· Source

• Completed

  An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

  NCT03921528· Phase 2· Scholar Rock, Inc.· Source

• Recruiting

  Two Dose Levels of Privigen in Pediatric CIDP

  NCT03684018· Phase 4· CSL Behring· Source

• Completed

  Hydroxyurea Optimization Through Precision Study

  NCT03789591· Phase 3· Lifespan· Source

• Terminated

  US Selumetinib Registry

  NCT05683678· Alexion Pharmaceuticals, Inc.· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· SK Life Science, Inc.· Source

• Completed

  Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

  NCT03566017· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

  NCT03569891· Phase 3· CSL Behring· Source

• Completed

  Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

  NCT03376438· Edgar Jaeggi· Source

• Completed

  Raising Healthy Children: A Hybrid Trial of the Family Check-Up 4 Health in Primary Care

  NCT03013309· Arizona State University· Source

• Completed

  A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

  NCT02927769· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

  NCT02148796· Phase 2· University of Arizona· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Incyte Corporation· Source

• Completed

  Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

  NCT02512926· Phase 1· Stanford University· Source

• Completed

  Apixaban for the Acute Treatment of Venous Thromboembolism in Children

  NCT02464969· Phase 4· Bristol-Myers Squibb· Source

• Completed

  Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer

  NCT01802567· Giselle Sholler· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Bristol-Myers Squibb· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Eosinophilic oesophagitis14 works · 0 trials
• Childhood cancers11 works · 35 trials
• Hydrocephalus9 works · 1 trial